Brought to you by 
Mallinckrodt pays $5.3bn in cash and stock for spec pharma Questcor
10 Sep 2020
Executive Summary
In its second major acquisition since the beginning of the year, Mallinckrodt PLC is paying $5.3bn to buy publicly traded specialty pharmaco Questcor Pharmaceuticals Inc. Questcor stockholders get $30 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor they own (the equivalent of roughly $86.10 per share, a 32% premium); post-merger ownership stakes come out to 50.5% Mallinckrodt, 49.5% Questcor.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mallinckrodt pays $5.3bn in cash and stock for spec pharma Questcor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice